ACAD - ACADIA Pharmaceuticals Inc Stock Price, Fair Value and News

14.77USD-0.08 (-0.54%)Delayed

Market Summary

USD14.77-0.08

Delayed

-0.54%

ACAD Alerts

1 major insider sales recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

ACAD Stock Price

View Fullscreen

ACAD RSI Chart

ACAD Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-1.4K

Price/Sales (Trailing)

EV/EBITDA

136.6

Price/Free Cashflow

38.33

ACAD Price/Sales (Trailing)

ACAD Profitability

EBT Margin

1.83%

Return on Equity

-0.37%

Return on Assets

-0.2%

Free Cashflow Yield

2.61%

ACAD Fundamentals

ACAD Revenue

Revenue (TTM)

813.8M

Rev. Growth (Yr)

73.75%

Rev. Growth (Qtr)

-10.91%

ACAD Earnings

Earnings (TTM)

-1.7M

Earnings Growth (Yr)

138.48%

Earnings Growth (Qtr)

-63.85%

Breaking Down ACAD Revenue

Last 7 days

-3.1%

Last 30 days

-14.1%

Last 90 days

-41.2%

Trailing 12 Months

-36.3%

How does ACAD drawdown profile look like?

ACAD Financial Health

Current Ratio

2.04

ACAD Investor Care

Shares Dilution (1Y)

1.60%

Diluted EPS (TTM)

-0.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	813.8M	0	0	0
2023	520.2M	550.9M	631.9M	726.4M
2022	493.1M	512.4M	511.5M	517.2M
2021	458.2M	463.4M	474.4M	484.1M
2020	366.2M	393.1M	419.1M	441.8M
2019	237.9M	264.0M	300.3M	339.1M
2018	158.5M	185.1M	207.8M	223.8M
2017	40.2M	63.0M	93.3M	124.9M
2016	4.4M	8.7M	13.0M	17.3M
2015	0	0	129.0K	118.0K
2014	758.0K	335.0K	110.0K	120.0K
2013	4.9M	4.7M	1.5M	1.1M
2012	2.1M	2.2M	5.1M	4.9M
2011	32.1M	22.1M	12.1M	2.1M
2010	0	18.3M	30.2M	42.1M
2009	0	0	0	6.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ACADIA Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	kihara james	sold	-22,462	16.94	-1,326	principal accounting officer
May 02, 2024	teehan brendan	sold	-58,900	16.94	-3,477	evp, coo, head of commercial
May 02, 2024	schneyer mark c.	sold	-59,340	16.94	-3,503	evp, chief financial officer
May 02, 2024	davis stephen	sold	-193,573	16.94	-11,427	ceo
May 01, 2024	schneyer mark c.	acquired	-	-	6,814	evp, chief financial officer
May 01, 2024	kihara james	acquired	-	-	2,596	principal accounting officer
May 01, 2024	teehan brendan	acquired	-	-	6,814	evp, coo, head of commercial
May 01, 2024	davis stephen	acquired	-	-	22,391	ceo
Apr 08, 2024	kihara james	sold	-31,987	17.87	-1,790	principal accounting officer
Apr 08, 2024	teehan brendan	sold	-45,890	17.87	-2,568	evp, coo, head of commercial

Which funds bought or sold ACAD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-15.74	-7,020,820	6,953,370	-%
May 16, 2024	Arete Wealth Advisors, LLC	new	-	295,840	295,840	0.03%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.16	-1,580,360	2,012,120	-%
May 16, 2024	COMERICA BANK	reduced	-97.77	-1,306,860	17,458	-%
May 15, 2024	CITADEL ADVISORS LLC	added	271	5,734,090	10,525,600	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	-	-689,127	990,515	-%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	sold off	-100	-304,584	-	-%
May 15, 2024	Alyeska Investment Group, L.P.	reduced	-85.35	-16,733,000	1,584,520	0.01%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-68.62	-8,895,330	2,023,340	-%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-29.63	-68,705,500	48,850,900	0.04%

Are Funds Buying or Selling ACAD?

Are funds buying ACAD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACAD

No. of Funds

Unveiling ACADIA Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rtw investments, lp	6.9%	11,253,551	SC 13G
Feb 13, 2024	vanguard group inc	8.16%	13,396,009	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	6.9%	11,409,218	SC 13G/A
May 24, 2023	baker bros. advisors lp	26.5%	43,084,280	SC 13D/A
Feb 14, 2023	price t rowe associates inc /md/	2.6%	4,279,254	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.20%	13,279,775	SC 13G/A
Feb 01, 2023	blackrock inc.	6.3%	10,258,738	SC 13G/A
Jan 17, 2023	baker bros. advisors lp	26.0%	42,163,470	SC 13D/A

Recent SEC filings of ACADIA Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 15, 2024	3	Insider Trading
Apr 09, 2024	4	Insider Trading

Peers (Alternatives to ACADIA Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

ACADIA Pharmaceuticals Inc News

Latest updates

ACADIA Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-10.9%	205,831,000	231,041,000	211,699,000	165,235,000	118,462,000	136,490,000	130,714,000	134,563,000	115,468,000	130,758,000	131,612,000	115,221,000	106,554,000	121,007,000	120,577,000	110,103,000	90,068,000	98,326,000	94,586,000	83,205,000	62,959,000
Costs and Expenses	-2.8%	190,621,000	196,097,000	269,475,000	162,198,000	172,046,000	182,553,000	161,580,000	168,214,000	228,484,000	175,415,000	146,913,000	158,930,000	173,326,000	188,169,000	206,476,000	154,113,000	179,583,000	154,725,000	140,007,000	140,296,000	150,593,000
S&GA Expenses	-3.1%	107,991,000	111,465,500	97,890,000	95,968,000	101,235,000	104,402,000	78,108,000	89,901,000	96,679,000	105,912,000	81,666,000	96,789,000	111,661,000	120,752,000	81,592,000	84,344,000	101,973,000	91,871,000	72,696,000	67,981,000	93,090,000
R&D Expenses	-10.6%	59,679,000	66,741,000	156,963,000	58,771,000	69,144,000	75,738,000	81,336,000	75,646,000	128,855,000	66,942,000	58,565,000	56,935,000	56,973,000	62,116,000	120,083,000	64,295,000	72,636,000	57,520,000	62,622,000	67,320,000	52,923,000
EBITDA Margin	129.5%	0.02	-0.07	-0.21	-0.19	-0.28	-0.41	-0.42	-0.39	-0.43	-0.34	-0.40	-0.56	-	-	-	-	-	-	-	-	-
Income Taxes	173.1%	4,447,000	-6,079,500	13,033,000	5,200,000	-1,918,000	809,500	800,000	443,000	500,000	189,000	-332,000	473,000	21,000	417,000	-199,000	393,000	-	400,000	-264,000	365,000	375,000
Earnings Before Taxes	-47.0%	21,002,000	39,662,000	-52,100,000	6,343,000	-44,939,000	-40,859,500	-26,415,000	-33,600,000	-112,600,000	-42,905,000	-14,789,000	-43,398,000	-66,427,000	-66,343,000	-84,859,000	-41,748,000	-88,023,000	-52,636,000	-42,242,000	-54,576,000	-84,929,000
EBT Margin	126.1%	0.02	-0.07	-0.21	-0.19	-0.28	-0.41	-0.42	-0.40	-0.43	-0.35	-0.40	-0.56	-	-	-	-	-	-	-	-	-
Net Income	-63.9%	16,555,000	45,797,000	-65,176,000	1,114,000	-43,021,000	-41,725,000	-27,183,000	-34,011,000	-113,056,000	-43,094,000	-14,457,000	-43,871,000	-66,448,000	-66,760,000	-84,660,000	-42,141,000	-88,023,000	-53,036,000	-41,978,000	-54,941,000	-85,304,000
Net Income Margin	97.5%	0.00	-0.08	-0.24	-0.20	-0.28	-0.42	-0.42	-0.40	-0.43	-0.35	-0.40	-0.56	-	-	-	-	-	-	-	-	-
Free Cashflow	-65.9%	29,079,000	85,389,000	-58,955,000	8,201,000	-17,933,000	-23,854,000	-727,000	-13,125,000	-76,329,000	-23,121,000	-17,064,000	-25,372,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	14.2%	855	749	633	643	655	588	602	613	624	700	718	724	755	783	796	760	747	783	766	461	501
Current Assets	9.6%	675	616	499	493	503	508	522	533	542	618	641	646	674	718	730	736	724	760	742	437	476
Cash Equivalents	8.5%	205	189	98.00	108	291	115	155	140	205	147	95.00	267	304	326	452	310	173	190	385	74.00	98.00
Inventory	64.8%	67.00	40.00	-	-	-	-	-	-	-	-	14.00	11.00	10.00	10.00	8.00	6.00	6.00	6.00	5.00	4.00	5.00
Net PPE	-5.2%	4.00	5.00	5.00	5.00	6.00	6.00	7.00	7.00	8.00	8.00	9.00	9.00	10.00	9.00	8.00	7.00	5.00	3.00	3.00	3.00	4.00
Liabilities	23.3%	391	317	270	247	281	187	177	178	179	159	151	160	174	156	141	97.00	109	84.00	76.00	72.00	83.00
Current Liabilities	30.0%	331	254	210	188	224	126	117	118	120	96.00	88.00	95.00	109	106	92.00	86.00	100	75.00	68.00	64.00	75.00
Shareholder's Equity	7.5%	464	432	362	396	374	400	426	435	445	541	567	565	582	627	655	663	638	699	689	389	418
Retained Earnings	0.7%	-2,414	-2,430	-2,476	-2,411	-2,412	-2,369	-2,327	-2,300	-2,266	-2,153	-2,110	-2,096	-2,052	-1,985	-1,918	-1,834	-1,792	-1,704	-1,651	-1,609	-1,554
Additional Paid-In Capital	0.6%	2,879	2,863	2,839	2,808	2,787	2,771	2,755	2,736	2,712	2,695	2,677	2,661	2,634	2,613	2,573	2,496	2,429	2,403	2,340	1,997	1,972
Shares Outstanding	0.2%	165	165	164	163	162	162	162	162	161	161	161	161	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,900	-	-	-	1,700	-	-	-	2,500	-	-	-	4,600	-	-	-	2,200	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-65.9%	29,079	85,389	-58,955	8,201	-17,933	-23,854	-727	-13,125	-76,329	-23,120	-17,064	-25,327	-60,149	-27,488	-22,793	-36,883	-49,002	-29,707	-18,851	-38,397	-64,175
Share Based Compensation	-18.2%	14,750	18,023	18,539	15,154	14,705	14,414	18,312	20,512	14,963	12,880	15,546	22,005	13,184	21,195	21,372	19,507	22,348	19,850	22,023	20,422	19,883
Cashflow From Investing	-3945.8%	-14,039	-347	34,110	-194,283	192,518	-17,748	15,441	-55,797	131,345	71,549	-156,321	-17,207	30,877	-116,958	152,994	126,865	29,608	-209,144	9,923	10,627	22,758
Cashflow From Financing	-80.8%	1,043	5,434	12,751	5,478	1,466	1,614	287	3,831	2,467	4,365	1,066	5,005	7,726	18,126	11,715	47,401	3,754	43,058	319,967	4,646	4,176

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACAD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Total revenues	$ 205,831	$ 118,462
Operating expenses
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Cost of product sales	$ 22,951	$ 1,667
Research and development	59,679	69,144
Selling, general and administrative	107,991	101,235
Total operating expenses	190,621	172,046
Income (loss) from operations	15,210	(53,584)
Interest income, net	5,506	3,800
Other income	286	4,845
Income (loss) before income taxes	21,002	(44,939)
Income tax expense (benefit)	4,447	(1,918)
Net Income (Loss)	$ 16,555	$ (43,021)
Earnings (net loss) per share, basic	$ 0.1	$ (0.27)
Earnings (net loss) per share, diluted	$ 0.1	$ (0.27)
Weighted average common shares outstanding, basic	164,798	162,263
Weighted average common shares outstanding, diluted	166,623	162,263

ACAD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 204,745	$ 188,657
Investment securities, available-for-sale	265,775	250,208
Accounts receivable, net	94,701	98,267
Interest and other receivables	5,378	4,083
Inventory	61,936	35,819
Prepaid expenses	42,761	39,091
Total current assets	675,296	616,125
Property and equipment, net	4,370	4,612
Operating lease right-of-use assets	54,280	51,855
Intangible assets, net	110,204	65,490
Restricted cash	5,770	5,770
Long-term inventory	4,707	4,628
Other assets	476	476
Total assets	855,103	748,956
Liabilities and stockholders’ equity
Accounts payable	19,332	17,543
Accrued liabilities	311,265	236,711
Total current liabilities	330,597	254,254
Operating lease liabilities	49,189	47,800
Other long-term liabilities	11,273	15,147
Total liabilities	391,059	317,201
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 andDecember 31, 2023	0	0
Common stock, $0.0001 par value; 225,000,000 shares authorized at March 31, 2024 and December 31, 2023; 164,959,736 shares and 164,650,219 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	16	16
Additional paid-in capital	2,878,539	2,862,552
Accumulated deficit	(2,414,282)	(2,430,837)
Accumulated other comprehensive loss	(229)	24
Total stockholders’ equity	464,044	431,755
Total liabilities and stockholders’ equity	$ 855,103	$ 748,956

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

CEO	Mr. Stephen R. Davis J.D.
WEBSITE	https://acadia.com
INDUSTRY	Biotechnology
EMPLOYEES	540

ACADIA Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for ACADIA Pharmaceuticals Inc? What does ACAD stand for in stocks?

ACAD is the stock ticker symbol of ACADIA Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ACADIA Pharmaceuticals Inc (ACAD)?

As of Fri May 17 2024, market cap of ACADIA Pharmaceuticals Inc is 2.44 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers. The fair value of ACADIA Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ACADIA Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACAD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ACADIA Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACAD is over valued or under valued. Whether ACADIA Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ACADIA Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACAD.

What is ACADIA Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ACAD's PE ratio (Price to Earnings) is -1427.08 and Price to Sales (PS) ratio is 3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACAD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ACADIA Pharmaceuticals Inc's stock?

In the past 10 years, ACADIA Pharmaceuticals Inc has provided -0.025 (multiply by 100 for percentage) rate of return.